Iovance Biotherapeutics, Inc.

Healthcare

NASDAQ:IOVA · NASDAQ Global Market

Market Cap $1.46B Beta 0.70 P/E (TTM) -4.8

$4.08 +3.03%

+$0.12 today

52W Low $1.66High $5.63

Vol 10.92M · Avg 14.56M

EPS (TTM)-$0.85

Biotechnology

Management

Put operating results in leadership context

Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.

Return Metrics

ROE, ROIC & ROA over time

Management

ROE

-56.0%

avg -52.0%

ROIC

-51.5%

avg -48.9%

ROA

-42.8%

avg -43.4%

Analysis

ROA is currently the strongest return metric at -42.8% versus its period average of -43.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Management

Key executives, compensation & ownership

Management

Name	Title	Compensation	Tenure	Age	Shares Owned	Ownership %
Frederick G. Vogt	Interim Chief Executive Officer, President, General Counsel, Corporate Secretary & Director	$1.13M	—	52	$109,382.00	0.03%
Raj K. Puri	Chief Regulatory Officer	$867,158.00	—	70	$251,957.00	0.07%
Daniel G. Kirby	Chief Commercial Officer	$804,031.00	—	54	$149,381.00	0.04%
Friedrich Graf Finckenstein	Chief Medical Officer	$764,634.00	—	59	$140,111.00	0.04%
Igor Bilinsky	Chief Operating Officer	$738,374.00	—	53	$137,896.00	0.04%
Corleen Roche	Chief Financial Officer	$494,150.00	—	60	$132,200.00	0.04%
Elma S. Hawkins	Advisor to the Board	$465,395.00	—	69	$275,000.00	0.08%
Howard Johnson	Chief Business Officer	—	—	66	—	—
Kevin Smyth	Executive Vice President of Quality	—	—	—	—	—
Tracy Winton	Executive Vice President of Human Resources	—	—	—	—	—
Matthew W. Rosinack	Principal Accounting Officer	—	—	54	$89,129.00	0.02%
Sara Pellegrino	Senior Vice President of Investor Relations & Corporate Communications	—	—	—	—	—
Marc R. Theoret	Senior Vice President of Regulatory Strategy	—	—	—	—	—
Brian Shew	Senior Vice President & Head of Digital and Information Technology	—	—	—	—	—